404 related articles for article (PubMed ID: 26161929)
1. Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review.
Pusceddu S; De Braud F; Festinese F; Bregant C; Lorenzoni A; Maccauro M; Milione M; Concas L; Formisano B; Leuzzi L; Mazzaferro V; Buzzoni R
Future Oncol; 2015; 11(13):1947-59. PubMed ID: 26161929
[TBL] [Abstract][Full Text] [Related]
2. Does combination of "cold" and "hot" somatostatin analogs prolong survival of patients with neuroendocrine neoplasms?
Sowa-Staszczak A; Stefanska A; Chrapczynski P; Trofimiuk-Müldner M; Szura M; Hubalewska-Dydejczyk A
Endocr J; 2017 Feb; 64(2):171-177. PubMed ID: 27853048
[TBL] [Abstract][Full Text] [Related]
3. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
Fazio N; Cinieri S; Lorizzo K; Squadroni M; Orlando L; Spada F; Maiello E; Bodei L; Paganelli G; Delle Fave G; de Braud F
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617
[TBL] [Abstract][Full Text] [Related]
4. Drug Development in Neuroendocrine Tumors: What Is on the Horizon?
Garcia-Alvarez A; Hernando Cubero J; Capdevila J
Curr Treat Options Oncol; 2021 Mar; 22(5):43. PubMed ID: 33786683
[TBL] [Abstract][Full Text] [Related]
5. Peritoneal Carcinomatosis in Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Clinical Impact and Effectiveness of the Available Therapeutic Options.
Merola E; Prasad V; Pascher A; Pape UF; Arsenic R; Denecke T; Fehrenbach U; Wiedenmann B; Pavel ME
Neuroendocrinology; 2020; 110(6):517-524. PubMed ID: 31484182
[TBL] [Abstract][Full Text] [Related]
6. Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.
Raj N; Reidy-Lagunes D
Hematol Oncol Clin North Am; 2016 Feb; 30(1):119-33. PubMed ID: 26614372
[TBL] [Abstract][Full Text] [Related]
7. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors.
Toumpanakis C; Caplin ME
Semin Oncol; 2013 Feb; 40(1):56-68. PubMed ID: 23391113
[TBL] [Abstract][Full Text] [Related]
8. The State of Peptide Receptor Radionuclide Therapy and Its Sequencing among Current Therapeutic Options for Gastroenteropancreatic Neuroendocrine Tumors.
Raymond LM; Korzun T; Kardosh A; Kolbeck KJ; Pommier R; Mittra ES
Neuroendocrinology; 2021; 111(11):1086-1098. PubMed ID: 33744879
[TBL] [Abstract][Full Text] [Related]
9. Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy.
Chan JA; Kulke MH
Surg Oncol Clin N Am; 2016 Apr; 25(2):423-37. PubMed ID: 27013373
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives.
Modica R; Liccardi A; Minotta R; Cannavale G; Benevento E; Colao A
Expert Rev Endocrinol Metab; 2022 Sep; 17(5):389-403. PubMed ID: 35822906
[TBL] [Abstract][Full Text] [Related]
11. GEPNETs update: Radionuclide therapy in neuroendocrine tumors.
van der Zwan WA; Bodei L; Mueller-Brand J; de Herder WW; Kvols LK; Kwekkeboom DJ
Eur J Endocrinol; 2015 Jan; 172(1):R1-8. PubMed ID: 25117465
[TBL] [Abstract][Full Text] [Related]
12. Advances in medical treatment for pancreatic neuroendocrine neoplasms.
Li YL; Cheng ZX; Yu FH; Tian C; Tan HY
World J Gastroenterol; 2022 May; 28(20):2163-2175. PubMed ID: 35721885
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches.
Lania A; Ferraù F; Rubino M; Modica R; Colao A; Faggiano A
Front Endocrinol (Lausanne); 2021; 12():651438. PubMed ID: 34381421
[TBL] [Abstract][Full Text] [Related]
14. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
[TBL] [Abstract][Full Text] [Related]
15. Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy.
Minczeles NS; Hofland J; de Herder WW; Brabander T
Curr Oncol Rep; 2021 Mar; 23(4):46. PubMed ID: 33721105
[TBL] [Abstract][Full Text] [Related]
16. Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors.
Hauser H; Gerson DS; Reidy-Lagunes D; Raj N
Curr Treat Options Oncol; 2019 Nov; 20(12):87. PubMed ID: 31776785
[TBL] [Abstract][Full Text] [Related]
17. Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors.
Narayanan S; Kunz PL
Hematol Oncol Clin North Am; 2016 Feb; 30(1):163-77. PubMed ID: 26614375
[TBL] [Abstract][Full Text] [Related]
18. Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer.
Bodei L; Kwekkeboom DJ; Kidd M; Modlin IM; Krenning EP
Semin Nucl Med; 2016 May; 46(3):225-38. PubMed ID: 27067503
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors.
Delaunoit T; Rubin J; Neczyporenko F; Erlichman C; Hobday TJ
Mayo Clin Proc; 2005 Apr; 80(4):502-6. PubMed ID: 15819288
[TBL] [Abstract][Full Text] [Related]
20. Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis.
Merola E; Panzuto F; Delle Fave G
Oncotarget; 2017 Jul; 8(28):46624-46634. PubMed ID: 28402955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]